OakChart

Castle Biosciences Inc

CSTLHealthcare·Diagnostics & Research·USA·Small·NASD·Nov 11 • 3:59 PM ET

33.99-0.43 (-1.25%)
2026-11-12 00:23 CET
Market cap
1,060.77 USD m
Revenue, TTM
377.13 USD m
Net income, TTM
-23.01 USD m
Free cash flow, TTM
3.96 USD m
EPS diluted, TTM
-0.77
P/E
-
Compare

Price

CSTL against its 20, 50 and 200-day averages
2050200beat
20.0025.0030.0035.00879K1.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CSTLclose 33.9920-day 34.3650-day 34.30200-day 28.2433.9952w low

23.2% under the 52-week high of 44.28 on 26 Jan 2026. 52-week low 17.72 on 14 May 2026. Last 15 sessions, 21.7% high to low

Volume 0.88× normal · the line is the 50-bar volume average

Profile

CSTL
52-week range, 61% of the way up
17.7244.28

Castle Biosciences, Inc. is a molecular diagnostics company, which offers innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett's esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

IndexRUT
Employees883
IPOJul 25, 2019
Beta0.96
ATR, 14d1.88
Rel volume0.88
Short float6.98%
Insider own2.00%
Inst own87.18%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.05B
Enterprise Value806.42M
Income-23.01M
Sales377.13M
Book/sh15.55
Cash/sh9.01
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees883
IPOJul 25, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S2.78
P/B2.19
P/C3.77
P/FCF264.52
EV/EBITDA-
EV/Sales2.14
Quick Ratio5.12
Current Ratio5.28
Debt/Eq0.08
LT Debt/Eq0.06
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.77
EPS next Y-0.62
EPS next Q-0.15
EPS this Y-2.95%
EPS next Y26.96%
EPS next 5Y80.00%
EPS past 3/5Y31.36% -8.93%
Sales past 3/5Y35.94% 40.60%
EPS Y/Y TTM-81.20%
Sales Y/Y TTM9.78%
EPS Q/Q-677.91%
Sales Q/Q23.90%
EarningsNov 05 AMC
EPS/Sales Surpr.62.62% 9.90%

Ownership

Insider Own2.00%
Insider Trans-36.91%
Inst Own87.18%
Inst Trans-5.75%
ROA-4.03%
ROE-4.87%
ROIC-4.52%
Gross Margin74.10%
Oper. Margin-7.43%
Profit Margin-6.10%
SMA20-1.08%
SMA50-0.92%
SMA20020.37%
Trades-

Technical

Shs Outstand30.77M
Shs Float30.20M
Short Float6.98%
Short Ratio5.55
Short Interest2.11M
52W High44.28 -23.24%
52W Low17.72 91.80%
Volatility6.34% 5.35%
ATR (14)1.88
RSI (14)48.53
Beta0.96
Rel Volume0.88
Avg Volume380.18K
Volume335,349

Performance

Perf Week-4.92%
Perf Month3.38%
Perf Quarter11.26%
Perf Half Y87.27%
Perf YTD-12.62%
Perf Year-2.80%
Perf 3Y97.85%
Perf 5Y-35.62%
Perf 10Y-
Recom1.10
Target Price48.20
Prev Close34.42
Price33.99
Change %-1.25%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
Oct 29, 2026InitiatedMMizuhoOutperform$60+76.5%
Jun 25, 2026InitiatedRRoth CapitalBuy$40+17.7%
Dec 14, 2023InitiatedGGuggenheimBuy$25-26.4%
Jan 05, 2023InitiatedBScotiabankSector Outperform$54+58.9%
Jan 07, 2022InitiatedSStephensOverweight$59+73.6%
Apr 30, 2021InitiatedLLake StreetBuy$94+176.6%
Nov 10, 2020InitiatedKKeyBanc Capital MarketsOverweight$70+105.9%
Dec 27, 2019ReiteratedCCanaccord GenuityBuy$34 → $35+3.0%
Aug 19, 2019InitiatedSSVB LeerinkOutperform$28-17.6%
Aug 19, 2019InitiatedRRobert W. BairdOutperform$27-20.6%

Peers

Mkt cap
TickerCompanyMkt cap
VCYTVeracyte Inc2.03B
MYGNMyriad Genetics Inc548.68M
NEONeogenomics Inc2.18B
MDXHMDxHealth SA13.98M
BDSXBiodesix Inc112.22M
XGNExagen Inc121.98M
GHGuardant Health Inc20.94B
NTRANatera Inc46.38B
LUCDLucid Diagnostics Inc77.52M
TEMTempus AI Inc14.49B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Tobin JuvenalChief Commercial OfficerNov 09 '26Proposed Sale34.3813,154452,235Nov 09 06:37 PM
MAETZOLD DEREK JPres. & Chief Exec. OfficerNov 02 '26Sale36.108,580309,7523,904Nov 04 04:07 PM
MAETZOLD DEREK JPres. & Chief Exec. OfficerNov 02 '26Sale36.105,916213,5781,396Nov 04 04:07 PM
Derek MaetzoldOfficerNov 02 '26Proposed Sale34.9421,438749,044Nov 02 05:28 PM
Juvenal Tobin WChief Commercial OfficerOct 28 '26Sale36.426,578239,59138,853Oct 30 04:06 PM
Juvenal Tobin WChief Commercial OfficerOct 26 '26Sale33.083,288108,76745,431Oct 28 04:08 PM
MAETZOLD DEREK JPres. & Chief Exec. OfficerOct 19 '26Sale31.918,580273,78812,484Oct 21 04:18 PM
MAETZOLD DEREK JPres. & Chief Exec. OfficerOct 19 '26Sale31.915,916188,7804,114Oct 21 04:18 PM
Juvenal Tobin WChief Commercial OfficerOct 12 '26Sale33.643,288110,60848,719Oct 14 04:06 PM
Tobin JuvenalChief Commercial OfficerOct 12 '26Proposed Sale32.7613,154430,925Oct 13 08:52 AM
MAETZOLD DEREK JPres. & Chief Exec. OfficerOct 05 '26Option Exercise2.398,16519,51429,644Oct 07 04:10 PM
MAETZOLD DEREK JPres. & Chief Exec. OfficerOct 05 '26Sale35.578,580305,15621,064Oct 07 04:10 PM
MAETZOLD DEREK JPres. & Chief Exec. OfficerOct 05 '26Sale35.575,916210,4086,832Oct 07 04:10 PM
Derek MaetzoldOfficerOct 05 '26Proposed Sale36.6528,9921,062,557Oct 05 06:24 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B

News

latest 14 of 100
  • Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference (PR Newswire)
  • DecisionDx-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging (PR Newswire)
  • Castle Biosciences Beats And Raises For A Third Time As TissueCypher Carries A Softening Dermatology Franchise (Earnings Whispers)
  • Castle Biosciences Reports Third Quarter 2026 Results (PR Newswire)
  • Castle Biosciences Faces A Higher Bar After Two Raises As TissueCypher Matures (Earnings Whispers) +6.29%
  • Castle Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
  • Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026 (PR Newswire)
  • ACG 2026 Data Show TissueCypher Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus (PR Newswire)
  • Late-Breaking EADV 2026 Data Support Use of DecisionDx-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management (PR Newswire)
  • New Study Shows That TissueCypher Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus (PR Newswire)
  • New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx (PR Newswire)
  • Castle Biosciences to Open New Laboratory Facility in Scottsdale (PR Newswire)
  • New Decision Modeling Study Demonstrates TissueCypher Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus (PR Newswire) +6.16%
  • JAAD Publication Shows Improved Performance of DecisionDx-SCC (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.130-0.348-0.130101.9592.7610
2026Q22026-07-30-0.070-0.407-0.068103.5586.239
2026Q12026-05-06-0.490-0.490-0.48684.2379.238
2025Q42026-02-26-0.080-0.259-0.08087.0179.898
2025Q32025-11-03-0.020-0.521-0.01783.0471.108
2025Q22025-08-040.150-0.5310.15386.1871.459
2025Q12025-05-05-0.900-0.069-0.90487.2080.319
2024Q42025-02-270.3200.0470.31885.8281.919
2024Q32024-11-040.080-0.0040.07785.7879.859
2024Q22024-08-050.310-0.2690.31086.6469.379
2024Q12024-05-02-0.090-0.332-0.09271.3266.559
2023Q42024-02-28-0.100-0.562-0.09566.1256.289
2023Q32023-11-02-0.260-0.764-0.25760.6148.578
2023Q22023-08-02-0.700-0.915-0.70250.2344.198
2023Q12023-05-03-1.100-0.891-1.09843.3737.418
2022Q42023-02-28-0.780-0.838-0.78138.3437.128

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.210-0.978-0.20851.8745.96
2020FY-0.540-0.406-0.54362.6561.11
2021FY-1.240-1.459-1.24594.0992.78
2022FY-2.580-2.722-2.577137.04135.89
2023FY-2.140-2.605-2.144219.79209.95
2024FY0.6200.3920.624333.82327.49
2025FY-0.830-1.039-0.830344.23336.22
2026FY--0.855--389.06
2027FY--0.624--433.42
2028FY--0.007--491.82
2029FY-0.840--602.55
2030FY-1.470--675.1

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-08980101.3892.98104.14
2026Q4S2026-11-061090101.3392.98104.14
2026Q4S2026-11-05102094.5692.28100.1
2026Q4S2026-10-28102094.5692.28100.1
2026Q4S2026-10-1692093.9592.2895.79
2026Q4S2026-10-1492093.9592.2895.79
2026Q4S2026-10-1196093.9592.2895.79
2026Q4S2026-10-0997093.9592.2895.79
2026Q4S2026-09-2496093.8192.2895.79
2026Q4S2026-09-2396093.6892.2894.80
2026Q4S2026-07-3196193.6892.2894.80
2026Q4S2026-07-2891192.1388.5093.62
2026Q4S2026-07-2590191.9388.5093.62
2026Q4S2026-07-2190291.9388.5093.62

Estimate history

EPS, annual-0.919-0.61-0.208-0.543-1.245-2.577-2.1440.624-0.833-0.767
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0770.318-0.9040.153-0.017-0.08-0.486-0.068-0.134
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual13.75422.78651.86562.64994.085137.039219.788332.069344.229377.13
Period201720182019202020212022202320242025TTM
Sales, quarterly85.78286.31187.98886.18883.04387.0183.679103.546102.891
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual16.64916.64917.13124.81225.37926.55427.41128.48329.68630.771
Period201720182019202020212022202320242025MRQ
Shares, quarterly27.97628.48328.84528.98129.16229.68630.29630.50930.771
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue377.13344.23332.07219.79137.0494.0862.6551.8722.79
Cost of Goods Sold Incl. D&A97.67107.8873.2555.5541.6818.759.827.395.46
Gross Profit279.46236.35258.82164.2395.3675.3352.8344.4717.33
Selling, General and Administrative Excl. Other307.49279.16250.15232.21186.50115.4161.2637.1521.17
Research and Development57.7651.4951.6953.2944.5729.4013.227.374.82
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-28.04-42.818.67-67.98-91.14-40.08-8.427.33-3.84
Interest Expense0.550.090.580.010.020.002.634.572.27
Unusual Expense4.37-0.98-0.560.00-18.290.00-0.48-2.28-
Net Income Before Taxes-22.62-29.5121.56-57.37-68.90-40.01-10.205.35-6.36
Income Taxes0.40-5.363.320.10-1.77-8.720.080.070.01
Consolidated Net Income-23.01-24.1618.25-57.47-67.14-31.29-10.285.28-6.37
Net Income From Continuing Operations-23.01-24.1618.25-57.47-67.14-31.29-10.285.28-6.37
Net Income-23.01-24.1618.25-57.47-67.14-31.29-10.282.99-10.16
EPS (Recurring)-0.65-0.860.61-2.14-3.07-1.24-0.56-0.39-0.61
EPS (Basic, Before Extraordinaries)-0.77-0.830.66-2.14-2.58-1.24-0.540.35-0.61
EPS (Diluted)-0.77-0.830.62-2.14-2.58-1.24-0.54-0.21-0.61
EBITDA-12.08-2.0424.67-55.65-80.60-36.67-7.957.69-3.51
Non-Operating Income (Expense)10.3412.4012.9210.623.970.070.370.31-0.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense34.7636.2639.7540.4628.6915.876.070.910.21
Price To Earnings Ratio--133.32------
Price To Sales Ratio2.893.282.352.634.4811.4520.295.74-
Gross Margin74.1068.6677.9474.7269.5980.0784.3385.7576.06
Operating Margin-7.43-12.442.61-30.93-66.51-42.60-13.4514.13-16.83
Net Margin-6.10-7.025.49-26.15-48.99-33.26-16.425.77-44.60
Shares Outstanding30.7729.6928.4827.4126.5525.3824.8117.1316.65
Market Capitalization1,060.771,060.77746.39580.73620.32864.081,353.46586.83598.27

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue102.89103.5583.6887.0183.0486.1987.9986.31
Cost of Goods Sold Incl. D&A26.7526.6223.3020.9921.5220.1345.2421.06
Gross Profit76.1476.9360.3866.0261.5366.0642.7465.25
Selling, General and Administrative Excl. Other78.8780.0078.7869.8468.3370.3170.6761.20
Research and Development15.6314.3914.3013.4412.8712.6912.4911.68
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.73-3.07-18.41-3.83-6.80-4.25-27.934.05
Interest Expense0.200.190.130.020.020.020.020.09
Unusual Expense3.420.63-2.022.34-3.56-1.191.43-0.56
Net Income Before Taxes-3.80-1.69-14.41-2.71-0.39-0.14-26.277.88
Income Taxes0.300.370.11-0.380.12-4.67-0.42-1.71
Consolidated Net Income-4.10-2.06-14.52-2.33-0.504.52-25.859.59
Net Income From Continuing Operations-4.10-2.06-14.52-2.33-0.504.52-25.859.59
Net Income-4.10-2.06-14.52-2.33-0.504.52-25.859.59
EPS (Recurring)-0.06-0.05-0.53-0.02-0.100.13-0.870.30
EPS (Basic, Before Extraordinaries)-0.13-0.07-0.49-0.08-0.020.16-0.900.34
EPS (Diluted)-0.13-0.07-0.49-0.08-0.020.15-0.900.32
EBITDA1.451.00-14.48-0.05-2.99-0.841.849.82
Non-Operating Income (Expense)2.552.202.113.482.882.943.103.37
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.879.167.729.019.568.858.839.04
Price To Earnings Ratio------32.66133.32
Price To Sales Ratio2.892.032.163.311.931.741.652.42
Gross Margin74.0074.2972.1575.8774.0976.6448.5875.60
Operating Margin-2.65-2.96-22.00-4.40-8.19-4.93-31.744.69
Net Margin-3.98-1.99-17.35-2.68-0.605.25-29.3811.11
Shares Outstanding30.7730.5130.3029.6929.1628.9828.8428.48
Market Capitalization1,060.77723.37729.901,135.44660.52589.57570.85746.39

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments299.50293.13243.10258.62329.63409.8598.844.481.21
Short Term Receivables43.3851.2238.3023.4817.2812.7614.6512.094.65
Inventories10.258.137.943.982.022.221.240.880.30
Other Current Assets7.967.676.296.214.814.771.950.680.52
Total Current Assets361.10360.15295.63292.29353.74429.59116.6818.136.68
Net Property, Plant & Equipment112.2462.7137.7426.5016.887.102.061.531.47
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable1.880.921.191.091.311.100.872.531.56
Intangible Assets99.57106.23117.33126.3588.92-0.000.000.04
Deferred Tax Assets30.6622.6824.4726.69-----
Other Assets3.771.231.441.111.721.540.140.210.06
Total Assets609.21553.92477.81474.02462.57439.33119.7522.409.82
Short Term Debt Incl. Current Port. of LT Debt1.842.041.141.781.180.005.830.001.00
Accounts Payable18.716.9010.274.732.552.101.861.451.12
Income Tax Payable-1.08---0.060.080.010.01
Other Current Liabilities48.1239.3736.2629.6221.1618.727.515.283.09
Total Current Liabilities68.6849.3947.6736.1324.8920.8815.296.745.22
Long Term Debt35.1724.4014.1711.536.900.0019.2926.0019.10
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities32.9924.2924.6827.120.64----
Other Liabilities1.500.000.030.0918.412.760.061.241.27
Total Liabilities138.3498.0886.5474.8750.8323.6434.6333.9825.59
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.0045.0034.54
Common Equity470.87455.83391.27399.15411.74415.6985.11-56.57-50.31
Total Shareholders Equity470.87455.83391.27399.15411.74415.6985.11-11.57-15.77
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity470.87455.83391.27399.15411.74415.6985.11-11.57-15.77
Total Liabilities & Stockholders Equity609.21553.92477.81474.02462.57439.33119.7522.409.82
Book Value Per Share15.8616.0014.2715.0316.2216.754.97-3.40-3.02
Tangible Book Value Per Share12.5112.279.9910.2712.7216.754.97-3.40-3.02
Full-Time Employees883761610543345201133--
Price to Book Ratio2.211.691.501.512.644.016.927.27-
Return on Assets-4.153.54-12.07-14.34-6.94-3.687.42-39.52-
Return on Equity-5.214.31-14.54-16.56-7.56-4.1114.35--
Return on Invested Capital-4.773.80-14.17-16.35-7.47-2.475.05-44.12-371.30
Quick Ratio5.117.136.047.9814.1320.477.552.561.22
Current Ratio5.267.296.208.0914.2120.587.632.691.28

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-23.01-24.1618.25-57.47-67.14-31.29-10.285.28-6.37
Depreciation15.9640.7716.0012.3310.543.410.470.360.32
Other Funds (Non Cash)46.7740.3650.0351.8518.1921.7410.531.341.11
Funds from Operations38.8750.7585.686.50-40.28-14.880.726.97-4.94
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.8813.60-14.12-6.63-0.01-4.109.150.04-7.36
Cash from Operating Activities39.7464.3571.55-0.14-40.29-18.989.877.01-12.29
Capital Expenditures-35.78-36.02-28.33-13.62-5.63-3.48-4.75-0.94-0.28
Net Assets From Acquisitions-0.00-18.730.000.00-26.97-63.180.000.000.00
Sale of Fixed Assets and Businesses0.030.040.020.010.740.010.000.00-
Purchase or Sale of Investments0.21-3.55-21.83-2.57-134.690.000.000.000.00
Purchase of Investments-202.97-194.28-205.73-189.07-134.690.000.000.000.00
Sale Or Maturity of Investments203.18190.73183.90186.500.000.000.000.000.00
Other Uses-2.11-2.110.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-37.66-60.37-50.14-16.18-166.54-66.66-4.75-0.94-0.28
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock3.502.212.020.270.833.90331.6367.1510.42
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock3.502.212.020.270.833.90331.6367.1510.42
Proceedsfrom Stock Options0.000.000.000.000.00-0.34330.0465.930.00
Issuance or Reduction of Debt, Net-0.10-0.129.90-0.14-0.12-0.01-27.3611.685.42
Change in Long Term Debt-0.10-0.129.90-0.14-0.12-0.01-27.3611.684.42
Issuance of Long Term Debt0.000.0010.000.000.000.000.0013.474.42
Reduction of Long Term Debt-0.10-0.12-0.10-0.14-0.12-0.01-27.36-1.790.00
Net Financing Active Other Cash Flow-13.04-9.05-5.78-2.420.801.531.619.450.00
Other Financing Activities Uses-16.68-11.66-8.76-5.13-1.69-0.780.000.000.00
Cash from Financing Activities-9.64-6.966.14-2.301.515.42305.8988.2915.84
Net Change in Cash-7.56-2.9827.55-18.62-205.32-80.22311.0194.373.27
Free Cash Flow3.9628.3343.23-13.76-45.92-22.475.116.08-12.57
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Price to Free Cash Flow274.6439.8118.04---248.5548.96-
Deferred Taxes & Investment Tax Credit--6.231.40-0.22-1.88-8.740.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments277.67266.81261.69299.50287.54275.93
Short Term Receivables52.1048.3442.2643.3849.4852.31
Inventories10.3810.5810.4610.258.658.37
Other Current Assets16.7115.3714.497.9611.8912.06
Total Current Assets356.86341.10328.90361.10357.57348.67
Net Property, Plant & Equipment125.43118.88115.36112.24100.0489.56
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets91.4995.1097.3599.57101.85104.12
Deferred Tax Assets---30.66--
Other Assets4.364.444.283.771.281.24
Total Assets579.41561.18547.80609.21562.79544.73
Short Term Debt Incl. Current Port. of LT Debt5.814.332.921.841.453.52
Accounts Payable13.229.6715.0418.7112.2113.18
Income Tax Payable----1.251.19
Other Current Liabilities48.5842.5130.8048.1240.4033.00
Total Current Liabilities67.6156.5148.7668.6855.3150.89
Long Term Debt30.7632.3233.8035.1735.6933.84
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities2.402.322.3332.993.243.13
Other Liabilities0.190.001.501.501.501.50
Total Liabilities100.9691.1586.39138.3495.7489.35
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity478.44470.03461.42470.87467.05455.38
Total Shareholders Equity478.44470.03461.42470.87467.05455.38
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity478.44470.03461.42470.87467.05455.38
Total Liabilities & Stockholders Equity579.41561.18547.80609.21562.79544.73
Book Value Per Share15.5515.4115.2315.8616.0215.71
Tangible Book Value Per Share12.5812.2912.0212.5112.5212.12
Full-Time Employees---883--
Price to Book Ratio2.211.571.552.431.451.34
Return on Assets-4.03-3.51-2.45-4.15-2.27-1.83
Return on Equity-4.87-4.20-2.85-5.21-2.69-2.15
Return on Invested Capital-0.81-0.41-2.93-0.46-0.100.92
Quick Ratio5.125.856.535.116.316.69
Current Ratio5.286.046.755.266.476.85

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-4.10-2.06-14.52-2.33-0.504.52
Depreciation4.184.073.933.783.823.41
Other Funds (Non Cash)14.4512.067.8312.427.709.04
Funds from Operations14.6114.07-2.7712.9611.1312.31
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.131.13-19.3613.9711.508.51
Cash from Operating Activities19.7415.20-22.1326.9322.6320.82
Capital Expenditures-7.49-8.65-12.46-7.18-14.83-9.26
Net Assets From Acquisitions0.000.000.00-0.000.00-18.73
Sale of Fixed Assets and Businesses0.010.010.010.010.020.01
Purchase or Sale of Investments2.75-7.32-13.3618.12-3.57-5.97
Purchase of Investments-55.95-54.49-55.14-37.41-58.47-49.97
Sale Or Maturity of Investments58.7047.1741.7855.5354.9044.00
Other Uses0.000.000.00-2.110.005.57
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-4.73-15.96-25.808.83-18.39-28.38
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.990.100.322.090.080.02
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.990.100.322.090.080.02
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.03-0.02-0.02-0.03-0.03-0.06
Change in Long Term Debt-0.03-0.02-0.02-0.03-0.03-0.06
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.03-0.02-0.02-0.03-0.03-0.06
Net Financing Active Other Cash Flow-0.10-0.96-5.33-6.65-0.960.14
Other Financing Activities Uses-0.92-1.79-6.60-7.37-1.19-0.56
Cash from Financing Activities0.87-0.89-5.03-4.59-0.920.10
Net Change in Cash15.88-1.65-52.9731.173.32-7.46
Free Cash Flow12.256.55-34.5819.757.8011.56
Price to Free Cash Flow274.64-162.4140.2820.6514.63

Revenue breakdown

Dermatologic2024: 257.00M 2025: 216.37M
Non-Dermatologic2024: 75.07M 2025: 127.86M
United States2024: 332.07M 2025: 344.23M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.98%2.1M30.2M398.18K
2026-10-156.74%2.0M29.9M403.29K
2026-09-306.68%2.0M29.9M390.44K
2026-09-156.35%1.9M29.9M397.67K
2026-08-316.61%2.0M29.9M400.19K
2026-08-145.87%1.8M29.9M403.27K
2026-07-315.24%1.6M29.8M430.09K
2026-07-154.81%1.4M29.6M394.72K
2026-06-305.05%1.5M29.5M399.62K
2026-06-155.03%1.5M29.5M371.82K
2026-05-295.03%1.5M29.5M392.92K
2026-05-154.78%1.4M29.6M410.38K
2026-04-304.83%1.4M29.6M374.60K
2026-04-154.95%1.5M29.6M387.49K
2026-03-315.30%1.5M28.9M404.87K
2026-03-134.94%1.4M28.9M400.99K
2026-02-274.82%1.4M28.9M402.12K
2026-02-134.78%1.4M28.4M404.31K
2026-01-305.33%1.5M28.4M441.99K
2026-01-155.40%1.5M28.4M414.13K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call17.5014.4018.600.005.1190.000.000.944-0.1100.006
call20.0012.0016.100.004.3370.000.000.932-0.1060.007
call22.509.4013.600.003.6500.000.000.918-0.1010.008
call25.006.9011.100.003.0280.000.000.898-0.0950.009
call30.002.256.306.002.0112.000.000.825-0.0750.014
call35.000.003.202.001.7196.000.000.510-0.2050.021
call40.000.002.300.051.1137940.000.198-0.0930.015
call45.000.002.150.801.5735.000.000.154-0.1120.013
call50.000.002.150.002.4780.000.000.219-0.2200.016
put17.500.002.150.003.8530.000.00-0.078-0.1680.008
put20.000.002.150.003.2390.000.00-0.093-0.1620.009
put22.500.002.150.002.8780.000.00-0.122-0.1750.011
put25.000.002.150.002.1850.000.00-0.136-0.1430.012
put30.000.002.351.000.9387530.00-0.175-0.0720.014
put35.000.904.102.401.6832.000.00-0.490-0.2010.021
put40.004.108.100.001.9720.000.00-0.802-0.0890.015
put45.009.0013.000.002.4740.000.00-0.846-0.1070.013
put50.0014.0018.000.002.9220.000.00-0.868-0.1190.011

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-29SCHEDULE 13G/ASEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100523.33K2
2026-10001.59M8
2026-09001.57M9
2026-08004.92M18
2026-07001.60M10
2026-0600469.18K5
2026-0500301.97K6
2026-0400350.90K4
2026-03003.63M13
2026-0200158.76K2
2026-0100316.43K3
2025-12002.71M9
2025-11001.85M11

Institutional holders

Manager% owned
BlackRock, Inc.10.85%
RTW INVESTMENTS, LP9.16%
PRINCIPAL FINANCIAL GROUP INC4.91%
VANGUARD CAPITAL MANAGEMENT LLC4.04%
Allianz Asset Management GmbH2.90%
ACADIAN ASSET MANAGEMENT LLC2.89%
VANGUARD PORTFOLIO MANAGEMENT LLC2.77%
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC2.72%
STATE STREET CORP2.71%
GEODE CAPITAL MANAGEMENT, LLC2.60%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.81%
Strategic Advisers U.S. Total Stock Fund2.60%
iShares Russell 2000 ETF2.58%
SmallCap Fund2.39%
VANGUARD EXTENDED MARKET INDEX FUND1.13%
Fidelity Small Cap Index Fund1.08%
iShares Russell 2000 Value ETF0.92%
VANGUARD EXPLORER FUND0.91%
Wasatch Micro Cap Fund0.91%
Buffalo Small Cap Growth Fund0.79%

OakChart. CSTL. Cached 15 minutes.